KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Sales (2016 - 2025)

Historic Return on Sales for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to 0.2%.

  • Alnylam Pharmaceuticals' Return on Sales rose 4200.0% to 0.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 1800.0%. This contributed to the annual value of 0.12% for FY2024, which is 1200.0% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Return on Sales is 0.2%, which was up 4200.0% from 0.09% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Return on Sales' 5-year high stood at 0.2% during Q3 2025, with a 5-year trough of 1.92% in Q1 2025.
  • For the 5-year period, Alnylam Pharmaceuticals' Return on Sales averaged around 0.65%, with its median value being 0.62% (2022).
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Return on Sales skyrocketed by 17300bps in 2023 and then crashed by -17800bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Return on Sales (Quarter) stood at 1.0% in 2021, then soared by 38bps to 0.62% in 2022, then soared by 49bps to 0.31% in 2023, then surged by 55bps to 0.14% in 2024, then soared by 242bps to 0.2% in 2025.
  • Its Return on Sales was 0.2% in Q3 2025, compared to 0.09% in Q2 2025 and 1.92% in Q1 2025.